Stereotaxis (STXS) Net Income towards Common Stockholders (2010 - 2026)
Stereotaxis' (STXS) quarterly Net Income towards Common Stockholders came in at -$6.2 million in Q1 2026, down 0.57% year-on-year from -$6.2 million in Q1 2025, and down 5.52% on a QoQ basis from -$5.8 million in Q4 2025.
Stereotaxis (STXS) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$6.2 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 0.57% year-over-year to -$6.2 million in Q1 2026; TTM through Mar 2026 was -$23.0 million, a 13.89% increase from a year earlier, with the FY2025 full-year figure at -$22.9 million, up 9.62% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$6.2 million, down from -$5.8 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for STXS reached as high as -$4.1 million in Q2 2025 and fell as low as -$7.8 million in Q4 2024.
- Historically, Net Income towards Common Stockholders has averaged -$5.7 million across 5 years, with a median of -$5.7 million in 2023.
- Across the five-year window, Net Income towards Common Stockholders plunged 253.75% in 2022 and soared 32.71% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$4.5 million in 2022, then dropped by 19.75% to -$5.4 million in 2023, then slumped by 45.73% to -$7.8 million in 2024, then gained by 25.39% to -$5.8 million in 2025, then retreated by 5.52% to -$6.2 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$6.2 million in Q1 2026, -$5.8 million in Q4 2025, and -$6.8 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 126.32 Bn | 121.10 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 44.69 Bn | 43.88 Bn | 2.15 Bn | -274.00 Mn |
| 3 | Alcon | 32.80 Bn | 31.14 Bn | 1.53 Bn | 22.13 Bn |
| 4 | Medline | 32.72 Bn | 30.49 Bn | 1.84 Bn | 239.00 Mn |
| 5 | Resmed | 29.54 Bn | 27.88 Bn | 890.98 Mn | 398.73 Mn |
| 6 | West Pharmaceutical Services | 23.56 Bn | 23.13 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 14.00 Bn | 13.44 Bn | 1.10 Bn | 13.00 Mn |
| 8 | Cooper Companies | 13.75 Bn | 13.61 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Align Technology | 12.03 Bn | 10.97 Bn | 736.59 Mn | 112.77 Mn |
| 10 | Stereotaxis | 128.56 Mn | 113.94 Mn | 3.79 Mn | -6.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.17 Mn |
| Dec 31, 2025 | -5.85 Mn |
| Sep 30, 2025 | -6.79 Mn |
| Jun 30, 2025 | -4.14 Mn |
| Mar 31, 2025 | -6.14 Mn |
| Dec 31, 2024 | -7.84 Mn |
| Sep 30, 2024 | -6.52 Mn |
| Jun 30, 2024 | -6.16 Mn |
| Mar 31, 2024 | -4.84 Mn |
| Dec 31, 2023 | -5.38 Mn |
| Sep 30, 2023 | -5.71 Mn |
| Jun 30, 2023 | -5.29 Mn |
| Mar 31, 2023 | -5.68 Mn |
| Dec 31, 2022 | -4.49 Mn |
| Sep 30, 2022 | -5.26 Mn |
| Jun 30, 2022 | -5.47 Mn |
| Mar 31, 2022 | -4.42 Mn |
| Dec 31, 2021 | -3.69 Mn |
| Sep 30, 2021 | -4.96 Mn |
| Jun 30, 2021 | -1.55 Mn |